Journal article
Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study
Z Chen, MJ Brodie, D Liew, P Kwan
JAMA Neurology | Published : 2018
Abstract
IMPORTANCE A study published in 2000 showed that more than one-Third of adults with epilepsy have inadequate control of seizures with antiepileptic drugs (AEDs). This study evaluates overall treatment outcomes in light of the introduction of more than 1 dozen new AEDs in the past 2 decades. OBJECTIVE To assess long-Term treatment outcome in patients with newly diagnosed and treated epilepsy. DESIGN, SETTING, AND PARTICIPANTS This longitudinal observational cohort studywas conducted at the Epilepsy Unit of theWestern Infirmary in Glasgow, Scotland. A total of 1795 individuals who were newly treated for epilepsy with AEDs between July 1, 1982, and October 31, 2012, were included in this analys..
View full abstractGrants
Funding Acknowledgements
Outside the submitted work, Dr Brodie serves on the scientific advisory boards of Eisai Ltd, UCB Pharma, GlaxoSmithKline, Lundbeck, Bial, GW Pharmaceuticals, and Takeda; is on the speakers' bureau for Eisai Ltd, UCB Pharma, GlaxoSmithKline, Lundbeck, Sanofi Aventis, and Abbott; and has accepted travel grants for scientific meetings from Eisai Ltd, UCB Pharma, and Lundbeck. Dr Liew has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, and the National Heart Foundation of Australia. He and/or his institution has also received speaker or consultancy fees and/or research grants from Pfizer, AbbVie, Sanofi, AstraZeneca, GlaxoSmithKline, and Amgen. Dr Kwan has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, the US National Institutes of Health, Hong Kong Research Grants Council, Innovation and Technology Fund, Health and Health Services Research Fund, and Health and Medical Research Fund. He and/or his institution also received speaker or consultancy fees and/or research grants from Eisai, GlaxoSmithKline, Johnson & Johnson, Pfizer, and UCB Pharma. No other disclosures are reported.